IL158735A0 - Novel ligand for nicotinic acetylcholine receptors useful in therapy - Google Patents

Novel ligand for nicotinic acetylcholine receptors useful in therapy

Info

Publication number
IL158735A0
IL158735A0 IL15873502A IL15873502A IL158735A0 IL 158735 A0 IL158735 A0 IL 158735A0 IL 15873502 A IL15873502 A IL 15873502A IL 15873502 A IL15873502 A IL 15873502A IL 158735 A0 IL158735 A0 IL 158735A0
Authority
IL
Israel
Prior art keywords
therapy
nicotinic acetylcholine
acetylcholine receptors
novel ligand
receptors useful
Prior art date
Application number
IL15873502A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL158735A0 publication Critical patent/IL158735A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15873502A 2001-06-01 2002-05-29 Novel ligand for nicotinic acetylcholine receptors useful in therapy IL158735A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29520601P 2001-06-01 2001-06-01
PCT/SE2002/001031 WO2002096912A1 (en) 2001-06-01 2002-05-29 Novel ligand for nicotinic acetylcholine receptors useful in therapy

Publications (1)

Publication Number Publication Date
IL158735A0 true IL158735A0 (en) 2004-05-12

Family

ID=23136711

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15873502A IL158735A0 (en) 2001-06-01 2002-05-29 Novel ligand for nicotinic acetylcholine receptors useful in therapy

Country Status (18)

Country Link
EP (1) EP1397366B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004532877A (cg-RX-API-DMAC7.html)
KR (1) KR20040003021A (cg-RX-API-DMAC7.html)
CN (1) CN1294136C (cg-RX-API-DMAC7.html)
AT (1) ATE353332T1 (cg-RX-API-DMAC7.html)
BR (1) BR0210075A (cg-RX-API-DMAC7.html)
CA (1) CA2455341A1 (cg-RX-API-DMAC7.html)
DE (1) DE60218032T2 (cg-RX-API-DMAC7.html)
DK (1) DK1397366T3 (cg-RX-API-DMAC7.html)
ES (1) ES2280538T3 (cg-RX-API-DMAC7.html)
IL (1) IL158735A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010996A (cg-RX-API-DMAC7.html)
NO (1) NO20035333D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ529426A (cg-RX-API-DMAC7.html)
PT (1) PT1397366E (cg-RX-API-DMAC7.html)
SI (1) SI1397366T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002096912A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308779B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7417050B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Heterocyclic compounds
KR20040099448A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 티에닐 화합물
EP1499618B1 (en) 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
KR20060094962A (ko) * 2003-10-21 2006-08-30 아스트라제네카 아베 스피로푸로피리딘 아릴 유도체
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
HRP20130234T1 (hr) 2008-06-20 2013-04-30 Astrazeneca Ab Derivat dibenzotiazepina i njegova uporaba
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289578A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
PT1397366E (pt) 2007-04-30
SI1397366T1 (sl) 2007-06-30
CN1512995A (zh) 2004-07-14
NZ529426A (en) 2005-07-29
DE60218032D1 (de) 2007-03-22
EP1397366B1 (en) 2007-02-07
JP2004532877A (ja) 2004-10-28
DE60218032T2 (de) 2007-08-16
DK1397366T3 (da) 2007-05-07
CN1294136C (zh) 2007-01-10
WO2002096912A1 (en) 2002-12-05
EP1397366A1 (en) 2004-03-17
ATE353332T1 (de) 2007-02-15
ZA200308779B (en) 2005-02-11
HK1063787A1 (en) 2005-01-14
CA2455341A1 (en) 2002-12-05
NO20035333D0 (no) 2003-11-28
MXPA03010996A (es) 2004-02-27
KR20040003021A (ko) 2004-01-07
BR0210075A (pt) 2004-08-17
ES2280538T3 (es) 2007-09-16

Similar Documents

Publication Publication Date Title
IL158735A0 (en) Novel ligand for nicotinic acetylcholine receptors useful in therapy
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
CY1113054T1 (el) Παραγωγα διαμινης
DE60112974D1 (en) Carbolinderivate
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
DE60325234D1 (de) Biaryldiazabicycloalkanamide als nicotinische acetylcholinagonisten
MXPA02011977A (es) Herbicidas de piridina sustituidas.
MXPA02012076A (es) Compuestos quimicos.
WO2002049641A3 (en) Anti-endoparasitic amidoacetonitrils
MXPA03007142A (es) Derivados de carbolina.
IL164613A0 (en) Thienyl compounds
AU2001266575A1 (en) Chemical compounds
PL1755397T3 (pl) Kompozycja chwastobójcza
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ATE370952T1 (de) Neue verbindungen
TW200508199A (en) Novel compound
TNSN05133A1 (en) Imidazoquinoline derivatives as adenosine a3 receptor ligands
MX2007006743A (es) Ligandos del receptor de acetilcolina nicotinica.
GB0018951D0 (en) Novel compounds
SI1197223T1 (cg-RX-API-DMAC7.html)
TR200402546T4 (tr) Taksan türevleri hazırlamak için işlem.
GB0027705D0 (en) Novel compounds
UA87813C2 (ru) Система контролируемого высвобождения темозоломида
MXPA04004937A (es) Proceso para preparar 3,3??,3,6??,-tetraalquil-2,2??-bifenoles y 3,??,6,??-tetraalquil-5,??-dihalo-2,??-bifenoles.
CA2421008A1 (en) Substituted heterocyclic compounds for treating multidrug resistance